PRRT works by exploiting the fact that many cancer cells have an abundance of specific receptors on their surfaces. The therapy uses peptides that can bind to these receptors. These peptides are labeled with a radionuclide, a radioactive isotope. When the peptide-radionuclide complex binds to the cancer cell receptors, the radioactivity is delivered directly to the cancer cells, causing DNA damage and ultimately cell death. This method is highly targeted, which minimizes damage to surrounding healthy tissues.
